Author:
Abraira Carlos,Duckworth William
Abstract
In Brief
Glycemic control is a well-established treatment objective in diabetes care. However, the effectiveness and specific goals of glycemic control are not yet known for older type 2 diabetic patients with advanced complications and suboptimal response to current treatments. Therefore, current glycemic guidelines for such patients are variable. This article presents the rationale for ongoing long-term clinical trials to answer these questions and reviews the demonstrated effectiveness of hypertension and dyslipidemia control in reducing both microvascular and macrovascular complications.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference34 articles.
1. Geiss S, Herman WH, Smith PJ: Mortality in non-insulin-dependent diabetes. In Diabetes in America. 2nd ed. Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, Eds. Bethesda, Md., National Institutes of Health, 1995, p. 133–155 (NIH publ. no. 95-1468)
2. Turner R, Cull C, Holman R: The effect of improved metabolic control on complications of NIDDM: UKPDS 17. Ann Intern Med 124:136–145, 1996
3. American Diabetes Association: Physicians rank diabetes as higher risk factor for CVD than smoking. Professional Section Quarterly, Summer 2002, p. 4
4. Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111:633–642, 2001
5. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L, on behalf of the DIGAMI Study Group: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 26:57–65, 1995
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献